The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance

Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt

Standard

The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance. / van Poppel, P C M; van Asseldonk, E J P; Holst, Jens Juul; Vilsbøll, Tina ; Netea, M G; Tack, C J.

I: Diabetes, Obesity and Metabolism, Bind 16, Nr. 12, 12.2014, s. 1269-73.

Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt

Harvard

van Poppel, PCM, van Asseldonk, EJP, Holst, JJ, Vilsbøll, T, Netea, MG & Tack, CJ 2014, 'The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance', Diabetes, Obesity and Metabolism, bind 16, nr. 12, s. 1269-73. https://doi.org/10.1111/dom.12357

APA

van Poppel, P. C. M., van Asseldonk, E. J. P., Holst, J. J., Vilsbøll, T., Netea, M. G., & Tack, C. J. (2014). The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance. Diabetes, Obesity and Metabolism, 16(12), 1269-73. https://doi.org/10.1111/dom.12357

Vancouver

van Poppel PCM, van Asseldonk EJP, Holst JJ, Vilsbøll T, Netea MG, Tack CJ. The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance. Diabetes, Obesity and Metabolism. 2014 dec.;16(12):1269-73. https://doi.org/10.1111/dom.12357

Author

van Poppel, P C M ; van Asseldonk, E J P ; Holst, Jens Juul ; Vilsbøll, Tina ; Netea, M G ; Tack, C J. / The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance. I: Diabetes, Obesity and Metabolism. 2014 ; Bind 16, Nr. 12. s. 1269-73.

Bibtex

@article{e8c7771cafa148939230218e718f5c91,
title = "The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance",
abstract = "Inflammation at the level of the β cell appears to be involved in progressive β-cell dysfunction in type 2 diabetes. We assessed the effect of blocking interleukin-1 (IL-1) by anakinra [recombinant human interleukin-1 receptor antagonist (IL-1Ra)] on β-cell function. Sixteen participants with impaired glucose tolerance were treated with 150 mg anakinra daily for 4 weeks in a double blind, randomized, placebo-controlled cross-over study with a wash-out period of 4 weeks. At the end of each treatment period, oral glucose tolerance tests (OGTTs) and hyperglycaemic clamps were performed. First-phase insulin secretion improved after anakinra treatment compared with placebo, 148 ± 20 versus 123 ± 14 mU/l, respectively (p = 0.03), and the insulinogenic index was higher after anakinra treatment. These results support the concept of involvement of IL-1β in the (progressive) decrease of insulin secretion capacity associated with type 2 diabetes.",
author = "{van Poppel}, {P C M} and {van Asseldonk}, {E J P} and Holst, {Jens Juul} and Tina Vilsb{\o}ll and Netea, {M G} and Tack, {C J}",
note = "{\textcopyright} 2014 John Wiley & Sons Ltd.",
year = "2014",
month = dec,
doi = "10.1111/dom.12357",
language = "English",
volume = "16",
pages = "1269--73",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "12",

}

RIS

TY - JOUR

T1 - The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance

AU - van Poppel, P C M

AU - van Asseldonk, E J P

AU - Holst, Jens Juul

AU - Vilsbøll, Tina

AU - Netea, M G

AU - Tack, C J

N1 - © 2014 John Wiley & Sons Ltd.

PY - 2014/12

Y1 - 2014/12

N2 - Inflammation at the level of the β cell appears to be involved in progressive β-cell dysfunction in type 2 diabetes. We assessed the effect of blocking interleukin-1 (IL-1) by anakinra [recombinant human interleukin-1 receptor antagonist (IL-1Ra)] on β-cell function. Sixteen participants with impaired glucose tolerance were treated with 150 mg anakinra daily for 4 weeks in a double blind, randomized, placebo-controlled cross-over study with a wash-out period of 4 weeks. At the end of each treatment period, oral glucose tolerance tests (OGTTs) and hyperglycaemic clamps were performed. First-phase insulin secretion improved after anakinra treatment compared with placebo, 148 ± 20 versus 123 ± 14 mU/l, respectively (p = 0.03), and the insulinogenic index was higher after anakinra treatment. These results support the concept of involvement of IL-1β in the (progressive) decrease of insulin secretion capacity associated with type 2 diabetes.

AB - Inflammation at the level of the β cell appears to be involved in progressive β-cell dysfunction in type 2 diabetes. We assessed the effect of blocking interleukin-1 (IL-1) by anakinra [recombinant human interleukin-1 receptor antagonist (IL-1Ra)] on β-cell function. Sixteen participants with impaired glucose tolerance were treated with 150 mg anakinra daily for 4 weeks in a double blind, randomized, placebo-controlled cross-over study with a wash-out period of 4 weeks. At the end of each treatment period, oral glucose tolerance tests (OGTTs) and hyperglycaemic clamps were performed. First-phase insulin secretion improved after anakinra treatment compared with placebo, 148 ± 20 versus 123 ± 14 mU/l, respectively (p = 0.03), and the insulinogenic index was higher after anakinra treatment. These results support the concept of involvement of IL-1β in the (progressive) decrease of insulin secretion capacity associated with type 2 diabetes.

U2 - 10.1111/dom.12357

DO - 10.1111/dom.12357

M3 - Letter

C2 - 25039318

VL - 16

SP - 1269

EP - 1273

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 12

ER -

ID: 132047707